Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 22, 2022 8:24pm
169 Views
Post# 34980593

RE:Morningstar's Quantitative Equity Research Report for ATE

RE:Morningstar's Quantitative Equity Research Report for ATEYes - interesting.  Thanks for the post.

Surely ... chronic had more uncertainty associated with it as it led us down the path to acute - for good reasons.

Also - acute likely leads us to strictly monitored chronic pain via pain specialists.
At higher dosing - wonder where it leads us on the peri-op side as well.

If we look at chronic over 14 days, we've handled 14 x 250 mg or 3500 mg in total without issue.
If we look at acute, going to guess less than 3000 mg over 10 days.

I think they forgot to add the word "less" in front of "extreme" in the uncertainty category.

Then again ... it's just my opinion.           :  )

<< Previous
Bullboard Posts
Next >>